Zhitong Finance App News, Hehuang Pharmaceutical (00013) issued an announcement to announce pre-clinical data of HMPL-A830 at the EORTC-NCI-AACR International Conference on Molecular Targeting and Cancer Treatment to be held in Barcelona, Spain from November 18 to 20, 2026. HMPL-A830 is the world's first (first-in-class) antibody-targeted conjugation drug (ATTC) candidate. It consists of a highly selective and potent KRAS small molecule inhibitor as the payload and conjugates it with an anti-epidermal growth factor receptor (EGFR) antibody.
RAS mutations are one of the most common and well-defined drivers in human oncology, driving the progression and aggressive pathologic features of various solid tumors. Although targeted therapies that have emerged in recent years have proven that KRAS (the most important RAS subtype) is a viable therapeutic target, there are still significant unmet clinical needs, including safety limitations and disease progression due to acquired drug resistance, which is mostly mediated by an increase in the upstream receptor tyrosine kinase. The HMPL-A830 is designed to address this unmet medical need by delivering KRAS inhibitors directly to EGFR-expressing tumors while blocking EGFR and KRAS signaling pathways, thereby improving efficacy, durability and tolerability.
In vitro studies have shown that its pan-KRAS payload has a dual mechanism of action and can simultaneously block KRAS in the activated (ON) state (that is, GTP-RAF1 binding) and the inactivated (OFF) state (that is, the conversion of GDP to GTP). Strong anti-proliferative activity was observed in 55 tumor cell lines covering various KRAS variants, including G12C, G12D, G12V, and G13D mutations, and wild-type amplification. HMPL-A830 shows high affinity for EGFR-positive cells and can be quickly endocytosed into cells. Furthermore, it also showed a strong bystander killing effect, effectively removing neighboring EGFR-negative tumor cells while retaining potent antibody-dependent cell-mediated cytotoxicity (ADCC).
In mouse models, HMPL-A830 showed strong, dose-dependent anti-tumor efficacy in various EGFR-positive tumor models carrying KRAS variants. Compared with KRAS G12C inhibitors, HMPL-A830 achieved longer-lasting tumor regression; its efficacy is also superior to various control protocols, including its unconjugated antibody, pan-RAS inhibitor (single agent or combination cetuximab/ cetuximab), and an antibody-conjugated drug (ADC) targeting TROP2 topoisomerase I (Topo I) inhibitors. Pharmacokinetics/pharmacodynamics analysis showed that compared with naked antibodies, HMPL-A830 inhibits the EGFR/KRAS downstream signaling pathway more strongly and longer; furthermore, the drug can maintain a stable drug-antibody ratio (DAR) in mouse, monkey and human plasma.
In September 2026, our subsidiary HUTCHMED (Shanghai) Limited (HUTCHMED) Limited (HUTCHMED) reached an exclusive development and licensing agreement with a subsidiary of GSK plc (GlaxoSmithKline), granting the GlaxoSmithKline subsidiary the right to develop and commercialize the HMPL-A830 on a global scale other than mainland China, Hong Kong, Macau and Taiwan. Hutchison Whampoa Pharmaceuticals (Shanghai) Co., Ltd. will be responsible for the HMPL-A830 global Phase I development project. The GlaxoSmithKline subsidiary will be responsible for all subsequent clinical development and commercialization activities in regions other than mainland China, Hong Kong, Macau and Taiwan.
An ongoing global phase I clinical trial is currently in phase Ia to evaluate the safety and efficacy of HMPL-A830 in the treatment of patients with unresectable, advanced, or metastatic solid tumors (NCT07718581).